NHS England to fund Hemlibra for patients with severe haemophilia
August 21, 2019Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma
NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
August 21, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure
August 20, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
California man gets eight years in prison for falsely labelling erectile dysfunction drug
August 20, 2019Manufacturing and Production FDA, erectile dysfunction, labellnig, pharma, tadalafil
A man from Walnut, California has been sentenced to eight years and four months in federal prison for illegally importing …
FDA turns down Sarepta’s DMD drug over safety concerns
August 20, 2019Manufacturing and Production DMD, FDA, approval safety, pharma, sarepta
The FDA has declined to approve Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) drug, citing safety concerns including risk of infection …
FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia
August 20, 2019Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia
The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …
Drop in prescriptions for antibiotic leads to fewer cases of superbug in Wales
August 20, 2019Manufacturing and Production AMR, Antibiotics, C difficile, C. difficile, pharma, superbug
Cuts to the number of prescriptions for antibiotics have led to a drop in the number of cases of the …
Finding the needle in the haystack of rare disease
August 19, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease
Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder
August 19, 2019Sales and Marketing Cancer, Cerlgene, FDA, Inrebic, pharma, rare disease
Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment …
British and American healthcare professionals predict further delays to Brexit as Europeans expect no-deal
August 19, 2019Sales and Marketing EU, UK, US, brexit, brexit delay, healthcare, no-deal, pharma
The majority of healthcare professionals in Europe, Britain and America think Brexit will happen. However they do not believe that …
AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis
August 19, 2019Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis
The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …
UK Government calls on social media companies to fight misinformation surrounding vaccines
August 19, 2019Sales and Marketing MMR, anti-vaxxers, measles, pharma, vaccination, vaccines
Boris Johnson has called on social media companies to come together to discuss ways in which they can promote accurate …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
Hundreds of patients turn to private cannabis clinics in UK
August 16, 2019Medical Communications Marijuana, NHS, UK, cannabis, medicinal cannabis, pharma
Hundreds of people have turned to private clinics, in an effort to gain access to medicinal cannabis in the UK, …
Top Ten most popular articles on Pharmafile.com this week!
August 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma
Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
Pfizer recall two batches of migraine drug Relpax
August 16, 2019Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall
Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …
Regeneron invest $800 million into New York facilities
August 15, 2019Medical Communications East Greenbush, New York, Regeneron, pharma
Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …
Regeneron therapy halves LDL cholesterol levels in rare genetic condition
August 15, 2019Research and Development Regeneron, evinacumab, pharma, rare disease
Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …
Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis
August 15, 2019Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis
Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
